<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002791</url>
  </required_header>
  <id_info>
    <org_study_id>A98</org_study_id>
    <nct_id>NCT04002791</nct_id>
  </id_info>
  <brief_title>Patent Hemostasis With Vasoband Versus TR Band</brief_title>
  <acronym>OPEN-Radial</acronym>
  <official_title>Randomized COmparison of Isolated Radial Artery ComPrEssioN Versus Radial and Ipsilateral Ulnar Artery Compression in Achieving Patent Hemostasis: OPEN-Radial Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Total Cardiovascular Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Total Cardiovascular Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients referred for cardiac catheterization to be performed using transradial access, a&#xD;
      randomized comparison will be performed with the primary endpoint of patency of radial artery&#xD;
      at the time of application of hemostatic compression band. The single radial only TR-Band&#xD;
      (Terumo, Japan) will be compared to the dual balloon Vasoband (Vasoinnovations, USA) capable&#xD;
      of ipsilateral ulnar artery compression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      TRA is increasing in utilization across the world due to its established benefits of&#xD;
      reduction in access site complications, cost, and increase in patient comfort (1). The most&#xD;
      common structural consequence of TRA is radial artery occlusion (RAO). It occurs in 2-10% of&#xD;
      patients undergoing TRA (2). Several pharmacologic as well as non-pharmacologic practices&#xD;
      have been associated with RAO. Maintaining a hardware profile smaller than the inner diameter&#xD;
      of radial artery has been associated with better radial artery patency rates after the&#xD;
      procedure (3). Use of unfractionated heparin and other parenteral anticoagulants administered&#xD;
      during the procedure has also been associated with reduction in RAO, with a dose-dependent&#xD;
      effect with better reduction with higher doses of heparin (4,5).&#xD;
&#xD;
      One of the most effective intervention for reduction of RAO is avoidance of flow cessation in&#xD;
      radial artery during hemostatic compression (6). This technique, called &quot;patent hemostasis&quot;,&#xD;
      has been shown to unequivocally and sizably reduce the incidence of RAO. In patients with&#xD;
      small diameter radial arteries as well as low blood pressures, the ability to achieve and&#xD;
      maintain patent hemostasis has been observed to be lower than those otherwise. In view of the&#xD;
      co-dominant nature of forearm arterial circulation, the radial and ulnar arteries are&#xD;
      interdependent and compression of ipsilateral ulnar artery has been shown to increase flow as&#xD;
      well as peak flow velocity in the radial artery (7). Ipsilateral ulnar artery compression&#xD;
      during hemostatic compression of a punctured radial artery, has been shown to sizably and&#xD;
      significantly reduce the incidence of RAO compared to patent hemostasis (8). Randomized and&#xD;
      observational datasets utilizing this technique published so far have been using two devices&#xD;
      to achieve radial and ulnar compression, with difficult ergonomics leading to frequent&#xD;
      dislodgment of ulnar compression during the radial artery hemostatic process.&#xD;
&#xD;
      The investigators intend to study the comparative efficacy of the first dedicated dual&#xD;
      compression device in achieving patent hemostasis compared to the current popular radial&#xD;
      artery compression device.&#xD;
&#xD;
      Patients and Methods:&#xD;
&#xD;
      Patients referred for diagnostic cardiac catheterization using TRA will be screened. Those&#xD;
      providing written informed consent, will be enrolled in the study. A transradial cardiac&#xD;
      catheterization will be performed using the standard technique as described below.&#xD;
&#xD;
      Catheterization Technique:&#xD;
&#xD;
      After sterile preparation as well as local anesthetic infiltration, 5 French hydrophilic&#xD;
      introducer sheath will be introduced in the radial artery using standard puncture technique&#xD;
      (9). Once the introducer is in the radial artery lumen, 200 Âµg of nitroglycerin, 2.5 mg of&#xD;
      verapamil and 5000 IU of unfractionated heparin will be administered intra-arterially. 5&#xD;
      French or lower profile hardware will be used as per operator discretion to complete the&#xD;
      procedure.&#xD;
&#xD;
      Once the procedure is completed, the patient will be randomized to:&#xD;
&#xD;
      Group 1, which will include patients receiving hemostatic compression using the current&#xD;
      standard of care TR band (Terumo Corporation, Japan). The band will be applied according to&#xD;
      the instructions for use, with optimal pressure applied to achieve full hemostasis.&#xD;
&#xD;
      Group 2, will consist of patients who will receive Vaso-band (VasoInnovations, Inc, USA),&#xD;
      applied according to instructions for use, with ulnar balloon inflated for the first 60&#xD;
      minutes of radial artery hemostatic compression, with the radial balloon inflated to obtain&#xD;
      full hemostasis, after the sheath is removed.&#xD;
&#xD;
      Primary Study End-point: Radial artery patency at 0-15 minutes after application of radial&#xD;
      artery hemostatic compression.&#xD;
&#xD;
      Monitoring of Patency:&#xD;
&#xD;
      The radial artery patency will be monitored immediately after application of the band using&#xD;
      reverse Barbeau test in both groups, and patency will be re-evaluated at 15 minutes after&#xD;
      band application, 30 minutes after band application, 60 minutes after band application, as&#xD;
      well as upon removal of the band at 120 minutes.&#xD;
&#xD;
      If longer duration of application of pressure with the band is necessary in either group to&#xD;
      achieve hemostasis, the bands will be applied for longer duration and the adequacy of&#xD;
      hemostasis will be evaluated every 15 minutes after 120-minute duration and the band removed&#xD;
      once adequately adequate hemostasis has been achieved.&#xD;
&#xD;
      Radial patency will be assessed at 60 minutes after the band is removed.&#xD;
&#xD;
      Baseline demographic as well as procedural data, pharmacologic data, as well as elaborately&#xD;
      data will be collected on every patient.&#xD;
&#xD;
      Statistical Analysis Plan:&#xD;
&#xD;
      Categorical variables will be expressed as proportions, and differences between the two&#xD;
      groups will be assessed using chi-square test, or Pearson test as deemed appropriate. Numeric&#xD;
      variables will be assessed for normality of the distribution, and will be expressed as mean&#xD;
      and standard deviation for normally distributed variables, and median as well as&#xD;
      interquartile range for those without normal distribution. Parametric tests will be used to&#xD;
      compare differences between the two groups for normally distributed numeric variables, and&#xD;
      nonparametric tests will be used in those variables with a non-normal distribution.&#xD;
      Multivariable analysis if necessary, will be performed using forward selection binary&#xD;
      logistic regression for categorical dependent variable and linear regression for numeric&#xD;
      variables. Received operative characteristic derived c-statistic will be used to assess the&#xD;
      stability of the model.&#xD;
&#xD;
      Sample Size Calculation:&#xD;
&#xD;
      Based on the available literature, using the current standard of care TR band, patent&#xD;
      hemostasis defined as patency of radial artery during hemostatic compression at 15 minutes&#xD;
      into compression is achievable in 75% of patients undergoing TRA. The only published&#xD;
      randomized trial using prophylactic ipsilateral ulnar artery compression during radial artery&#xD;
      hemostatic compression has shown 96% achievement of patent hemostasis at 15 minutes after&#xD;
      onset of compression. Using this using these data, using a chi-square model, a sample size of&#xD;
      250 to 300 patients equally divided between two groups, is necessary to achieve a 90% power&#xD;
      with an alpha editor of 0.05. Expecting a 10% crossover rate will be accommodated a sample&#xD;
      size of 200 patients will be needed. After randomizing 200 patients, an interim analysis will&#xD;
      be performed. If event rates are low, the sample-size will be increased to 350 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2019</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized comparison of patent hemostasis achievement with single bladder radial artery compression device with a dual-bladder ulnar compression capable radial artery compression device.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Achieved Patent Hemostasis</measure>
    <time_frame>0-15 minutes</time_frame>
    <description>Patent hemostasis achievement at 0-15 minutes after onset of radial artery hemostatic compression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Radial Artery Occlusion One Hour After Removal of Hemostatic Compression</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Absence of Patency of radial artery at 1-hour after removal of hemostatic compression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Radial Artery Injury at Wrist and Hand Level</condition>
  <arm_group>
    <arm_group_label>Group 1: TR Band Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Vaso-band Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VasoBand</intervention_name>
    <description>Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
    <arm_group_label>Group 1: TR Band Arm</arm_group_label>
    <arm_group_label>Group 2: Vaso-band Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred for cardiac catheterization undergoing transradial access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ipsilateral radial artery cannulation, oral systemic anticoagulation therapy,&#xD;
             thrombolytic therapy in the previous 7 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas M Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apex Heart Institute, Ahmedabad, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apex Heart Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <results_first_submitted>September 7, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be deidentified and will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT04002791/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: TR Band Arm</title>
          <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Vaso-band Arm</title>
          <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: TR Band Arm</title>
          <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Vaso-band Arm</title>
          <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="10"/>
                    <measurement group_id="B2" value="59" spread="11"/>
                    <measurement group_id="B3" value="58" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>INDIAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous PCI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous CABG</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165" lower_limit="160" upper_limit="170"/>
                    <measurement group_id="B2" value="165" lower_limit="159" upper_limit="170"/>
                    <measurement group_id="B3" value="165" lower_limit="160" upper_limit="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="65" upper_limit="80"/>
                    <measurement group_id="B2" value="71" lower_limit="65" upper_limit="80"/>
                    <measurement group_id="B3" value="71" lower_limit="65" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>Gram/Dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.5" lower_limit="12" upper_limit="14.8"/>
                    <measurement group_id="B2" value="13.2" lower_limit="12.2" upper_limit="14.2"/>
                    <measurement group_id="B3" value="13.3" lower_limit="12.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets</title>
          <units>Cells x1000/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270" lower_limit="209.5" upper_limit="322.5"/>
                    <measurement group_id="B2" value="250.5" lower_limit="214.8" upper_limit="310.2"/>
                    <measurement group_id="B3" value="261" lower_limit="214" upper_limit="318.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.91" lower_limit="0.76" upper_limit="1"/>
                    <measurement group_id="B2" value="0.91" lower_limit="0.75" upper_limit="1.1"/>
                    <measurement group_id="B3" value="0.91" lower_limit="0.75" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wrist Circumference</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" lower_limit="20" upper_limit="23"/>
                    <measurement group_id="B2" value="20" lower_limit="19" upper_limit="23"/>
                    <measurement group_id="B3" value="20" lower_limit="19" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barbeau Test Pattern A</title>
          <description>Barbeau Test is performed by placing a plethysmographic sensor on the index finger after which the radial artery is compressed to the point of occlusion, and the plethysmographic waveform is analyzed, categorized into 4 categories.&#xD;
Pattern A is when the waveform shows no change from its baseline. Pattern B is when the waveform shows a decrease in amplitude from its baseline. Pattern C is when the waveform disappears but returns in &lt; 2 minutes. Pattern D is when the waveform disappears and fails to return in &lt; 2 minutes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barbeau Test Pattern B</title>
          <description>Barbeau Test is performed by placing a plethysmographic sensor on the index finger after which the radial artery is compressed to the point of occlusion, and the plethysmographic waveform is analyzed, categorized into 4 categories.&#xD;
Pattern A is when the waveform shows no change from its baseline. Pattern B is when the waveform shows a decrease in amplitude from its baseline. Pattern C is when the waveform disappears but returns in &lt; 2 minutes. Pattern D is when the waveform disappears and fails to return in &lt; 2 minutes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barbeau Test Pattern C</title>
          <description>Barbeau Test is performed by placing a plethysmographic sensor on the index finger after which the radial artery is compressed to the point of occlusion, and the plethysmographic waveform is analyzed, categorized into 4 categories.&#xD;
Pattern A is when the waveform shows no change from its baseline. Pattern B is when the waveform shows a decrease in amplitude from its baseline. Pattern C is when the waveform disappears but returns in &lt; 2 minutes. Pattern D is when the waveform disappears and fails to return in &lt; 2 minutes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Achieved Patent Hemostasis</title>
        <description>Patent hemostasis achievement at 0-15 minutes after onset of radial artery hemostatic compression</description>
        <time_frame>0-15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TR Band Arm</title>
            <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Vaso-band Arm</title>
            <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieved Patent Hemostasis</title>
          <description>Patent hemostasis achievement at 0-15 minutes after onset of radial artery hemostatic compression</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Radial Artery Occlusion One Hour After Removal of Hemostatic Compression</title>
        <description>Absence of Patency of radial artery at 1-hour after removal of hemostatic compression</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: TR Band Arm</title>
            <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Vaso-band Arm</title>
            <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Radial Artery Occlusion One Hour After Removal of Hemostatic Compression</title>
          <description>Absence of Patency of radial artery at 1-hour after removal of hemostatic compression</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The event of Forearm Hematoma was assessed in the time period of the procedure, from the point of obtaining arterial access to the point of discharge from the catheterization laboratory, up to 4 hours or similar The event of Rebound Bleeding was assessed in the time period after removal of hemostatic compression band up to 1 hour or similar which is typically 4 hours or similar from the time of arterial puncture.</time_frame>
      <desc>Forearm Hematoma is a new swelling in the forearm as a result of bleeding Rebound Bleeding is bleeding restarting at the access site after hemostasis was achieved</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: TR Band Arm</title>
          <description>Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using &quot;Patent hemostasis protocol&quot; to achieve full hemostasis.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Vaso-band Arm</title>
          <description>Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.&#xD;
VasoBand: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Forearm Hematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rebound Bleeding</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single-center, single-country study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chairman</name_or_title>
      <organization>Apex Heart Institute</organization>
      <phone>011 91 9824030576</phone>
      <email>theheartworld@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

